Biguanide medicine · Fact sheet

Metformin

Also known as Glucophage · metformin hydrochloride

Metformin is FDA approved to improve glycemic control in type 2 diabetes, not to slow aging or extend lifespan. The anti-aging case remains a research hypothesis, and controlled studies have also found tradeoffs such as blunted muscle growth during resistance training.

FDA approved for specific usesStrong human evidence for approved uses

What is Metformin?

Metformin is a biguanide medicine that lowers liver glucose production and improves aspects of glucose metabolism.

Its low cost, long clinical history, and effects on metabolic and cellular pathways made it a major drug-repurposing candidate in geroscience.

Benefits & claims

Observational studies in people with diabetes have associated metformin use with some favorable age-related outcomes, but treatment selection and underlying health make causal interpretation difficult.

Small trials such as MILES test biomarkers and tissue responses; they do not establish that metformin prevents aging-related disease in otherwise healthy people.

What the evidence supports

  • Metformin's glucose-lowering benefits in type 2 diabetes are established.
  • Geroscience studies have measured changes in gene expression and metabolic pathways, but these surrogate findings do not prove longer or healthier life.
Research areas
  • Type 2 diabetes
  • Cellular and metabolic aging biomarkers
  • Prevention of multiple age-related diseases
  • Interactions with exercise adaptation

Dosage & frequency

Product-specific label information

The labeled diabetes regimen is formulation- and age-specific. These amounts do not establish metformin as an anti-aging prescription.

Metformin hydrochloride immediate-release

Adults with type 2 diabetes

Amount
Start 500 mg twice daily or 850 mg once daily; labeled maximum 2,550 mg/day in divided doses
Frequency
Daily, with meals
Route studied or labeled
Oral

Titrated by tolerability and glucose response; renal restrictions apply.

Metformin hydrochloride immediate-release: pediatric

Patients age ten years and older with type 2 diabetes

Amount
Start 500 mg twice daily; maximum 2,000 mg/day in divided doses
Frequency
Daily, with meals
Route studied or labeled
Oral

Not the adult maximum or extended-release regimen.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Immediate-release and extended-release tablets have different schedules.

Interactions & precautions

  • The label addresses renal function, iodinated contrast, alcohol, carbonic anhydrase inhibitors, and medicines that reduce metformin clearance.

What is still unresolved

  • Benefits for healthy people without diabetes remain under study.

Side effects & risks

  • FDA labeling carries a boxed warning for rare but serious lactic acidosis, with risk shaped by kidney function and other clinical factors.
  • Common adverse effects are gastrointestinal; longer use can be associated with vitamin B12 deficiency.
  • A randomized trial in older adults found metformin blunted muscle hypertrophy from progressive resistance training, illustrating that pathway effects may involve tradeoffs.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

There is strong evidence for diabetes treatment, but no completed large randomized trial showing that metformin extends life or delays multiple age-related diseases in people without its established metabolic indications.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Appetite: reported experiences

Positive account · personal report

Less craving with gradual weight loss

A commenter described fewer cravings and steady weight loss with extended-release metformin, with fewer stomach problems than their earlier experience.

Amount, frequency, route and duration could not be confirmed for this account.

Diet, activity and diagnosis were not documented. The formulation comparison is personal, not a controlled comparison.

Read the original account
Mixed account · personal report

Early benefits, later diarrhea, then improvement

An author reported less hunger, more energy and weight loss over a year, followed by new diarrhea. Their update said digestive symptoms settled after changes in exposure, exercise and meals.

Reported use in this account

Product
Glucophage, described as regular rather than extended release
Amount
850 mg at the time of the symptoms; earlier starting amount 500 mg
Frequency
Three times a day at the time of the symptoms
Route
Not specified clearly
Duration
About one year

Other exposures described: Increased exercise; Changes in medicine exposure and meal timing during follow-up

Several things changed together, so the symptom pattern does not prove a drug reaction or an effective remedy.

Read the original account
Negative account · personal report

Headaches, aches and low energy early on

A person describing PCOS reported headaches, body aches, very low energy and reduced appetite soon after starting metformin, without diarrhea.

Reported use in this account

Product
Metformin; formulation not stated
Amount
250 mg at breakfast and 250 mg at lunch, as reported
Frequency
Twice daily
Route
Not specified clearly
Duration
Not specified clearly

The account is brief and lacks glucose readings, a clinical assessment or follow-up.

Read the original account

Approval status

Metformin is FDA approved for glycemic control in type 2 diabetes. Aging, lifespan extension, and general healthspan enhancement are not FDA-approved indications.

Approved uses

  • Improving glycemic control in people with type 2 diabetes as specified in FDA-approved labeling

FDA approved for type 2 diabetes, not aging

Metformin is FDA approved for glycemic control in type 2 diabetes. Aging, longevity, and exercise-response questions remain separate research uses.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether metformin improves lifespan or healthspan in people without diabetes
  • Which age, metabolic profile, or biomarker could identify a favorable risk-benefit group
  • How exercise, nutrition, and other medicines modify any geroscience effect
  • Whether observational associations reflect the drug or differences between patient groups

Summary

Metformin has established diabetes uses. It has not been shown to extend lifespan in healthy people.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA prescribing information: Glucophage and Glucophage XR

    Official indication, boxed warning, contraindications, and adverse reactions.

  2. clinical trialsClinicalTrials.gov: Metformin in Longevity Study

    Small completed mechanistic study of tissue and metabolic responses, not a lifespan trial.

  3. pubmedMASTERS randomized exercise trial

    Controlled trial reporting blunted muscle hypertrophy with metformin during resistance training in older adults.

  4. nihMetformin immediate-release current prescribing information

    Primary source for the practical reference information.

How we assess sources · Suggest a correction